Abstract 14277: Catheter Ablation of Atrial Fibrillation Without Dabigratan Discontinuation: Preliminary Safety and Efficacy Data
Introduction: Catheter ablation of atrial fibrillation is associated with a potential risk of periprocedural stroke/TIA and bleeding complications. In this multicenter study we sought to determine the safety and the efficacy of the ablation procedures performed without dabigratan discontinuation.
Methods: 92 consecutive patients undergoing catheter ablation for AF while anticoagulated with dabigratan 150mg bid, have been enrolled in this multicenter study. In all cases dabigratan was discontinued the day of the procedure and administered again after the procedure. In all cases during the procedures the ACT level was maintained above 300 sec and protamine was used at the end of the procedure to reverse the heparin effect. All patients underwent TEE before procedures to look for left atrial thrombus formation.
Results: The Baseline clinical and procedural characteristics are presented in the table. CHAD2 score was 0 in 29 (32%) pts, 1 in 48 (52%) pts, and ≥2 in 15 (16%) pts. TEE was negative in all patients. To restore sinus rhythm, cardioversion was necessary in 26 pts (28%). We observed 3 groin hematomas (3.3%), 1 stroke (1.09%) and 1 TIA (1.09%). Two pericardial effusions (2.2%) occurred during the procedure which did not require drainage. Three haemopericarditis (3.3%) were observed within 5 days following the procedures and were treated with aspirin and colchicine.
Conclusion: Catheter ablation of atrial fibrillation performed without dabigratan discontinuation appeared associated with a small increase of periprocedural complications. Further evaluations are warranted to confirm our preliminary results.
- © 2011 by American Heart Association, Inc.